Heterocyclic adenosine receptor antagonists
Patent Number 12264161 - April 1, 2025
Heterocyclic compounds useful as antagonists of adenosine receptors, and methods of treatment of diseases using antagonists of adenosine…
Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
Patent Number 12227481 - February 18, 2025
The invention relates to novel crystalline solid forms of salts of the chemical compound…
Compounds for the treatment of kinase-dependent disorders
Patent Number 12195475 - January 14, 2025
Disclosed herein are compounds of Formula (I?). Compounds of Formula (I?) inhibit, regulate and/or modulate kinase receptor, particularly Axl…
Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
Patent Number 12128039 - October 29, 2024
The present invention is directed to processes for making and compositions containing quinolines such as formula I or pharmaceutically…
Anti-ROR antibody constructs
Patent Number 12084496 - September 10, 2024
Anti-ROR antibody constructs, pharmaceutical compositions comprising the constructs, and methods of use thereof are presented.
PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES
Application Number 20250099604 - March 27, 2025
Provided herein are pharmaceutical compositions comprising anti-tissue factor antibody-drug conjugates (ADCs) and pharmaceutically acceptable…
ANTI-ROR ANTIBODY CONSTRUCTS
Application Number 20240392002 - November 28, 2024
Anti-ROR antibody constructs, pharmaceutical compositions comprising the constructs, and methods of use thereof are presented.
MULTISPECIFIC BINDING AGENTS AND USES THEREOF
Application Number 20240010751 - January 11, 2024
The present disclosure provides multispecific binding agents (e.g., antibodies, such as bispecific antibodies) that have a first binding…
MULTISPECIFIC BINDING AGENTS AND USES THEREOF
Application Number 20240010751 - January 11, 2024
The present disclosure provides multispecific binding agents (e.g., antibodies, such as bispecific antibodies) that have a first binding…
CD47 BINDING AGENTS AND USES THEREOF
Application Number 20230357391 - November 9, 2023
The present disclosure provides CD47 binding agents (e.g., antibodies, including multispecific antibodies, such as bispecific antibodies) and…
Exelixis, Inc. v. Biocon Pharma Limited et al
Delaware District Court - April 11, 2025
Exelixis, Inc. v. Sun Pharmaceutical Industries Ltd. et al
Delaware District Court - April 4, 2025
Exelixis, Inc. v. MSN Laboratories Private Limited et al
Delaware District Court - March 19, 2025
Exelixis, Inc. v. MSN Laboratories Private Ltd.
U.S. Court of Appeals, Federal Circuit - December 3, 2024
Exelixis, Inc. v. MSN Laboratories Private Ltd.
U.S. Court of Appeals, Federal Circuit - December 2, 2024
Exelixis, Inc. v. MSN Laboratories Private Limited et al
Delaware District Court - October 15, 2024
TRIAL OPINION: For the foregoing reasons, I find the asserted claim of the '349 patent not infringed and not invalid. I find the…
Exelixis, Inc. v. MSN Laboratories Private Limited et al
Delaware District Court - April 20, 2022
MEMORANDUM ORDER: I DENY the Daubert motion. (D.I. 257). The issue could be appropriate for a motion in limine, although based on what is…
Exelixis, Inc. v. Honorable David J. Kappos
Virginia Eastern District Court - January 28, 2013
MEMORANDUM OPINION in re 16 Motion for Summary Judgment and 13 Motion for Summary Judgment. Signed by District Judge Leonie M. Brinkema…
Exelixis, Inc. v. MSN Laboratories Private Limited et al
Delaware Delaware District Court - October 15, 2024
TRIAL OPINION: For the foregoing reasons, I find the asserted claim of the '349 patent not infringed and not invalid. I find the asserted…
Exelixis, Inc. v. MSN Laboratories Private Limited et al
Delaware Delaware District Court - January 19, 2023
TRIAL OPINION: MSN failed to prove by clear and convincing evidence that claims 5 of the '473 patent is invalid as obvious. Exelixis…
Artt v. Exelixis US LLC
Texas Texas Northern District Court - March 28, 2022
MEMORANDUM OPINION AND ORDER granting 19 Motion for Summary Judgment. (Ordered by Senior Judge A. Joe Fish on 3/28/2022) (jmg)
